Home / Stocks / GKOS

Glaukos (GKOS, Medical devices) Stock Valuation & Fair Value

Significantly overvalued

Glaukos (GKOS, Medical devices) trades at a current P/E of 601.5, about 156% above its historical normal valuation, with a forward growth estimate above 100% and a PEG of 4.46. Analysts' one-year estimates have been hit 10% of the time. Priced at its historical normal P/E of 234.5 on the same blended earnings, the 2026-10-30 close of $237.60 corresponds to about $92.60 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-02
Current P/E
601.5
Normal P/E
234.5
PEG
4.46
Fwd growth
>100%
Div yield
0.0%
RSI (14)
82.6
Overbought
Technical context
  • Price $237.60 at the Oct 30 close, 33.8% above the 20-day average ($177.52) and 37.1% above the 50-day ($173.29).
  • RSI (14) at 82.6.
  • 52-week range $81.79 to $242.48: the price is 2.0% below the high and 190.5% above the low.

The Street vs SeerForecast

Wall Street's mean price target for GKOS is $243.92 across 12 analysts, 2.7% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer published no valuation rating on 2026-10-24, and rates it significantly overvalued as of 2026-11-02.

Price and rating by weekClose moved +32.8 percent from 2026-10-23 to 2026-10-30, with 0 rating changes over 2 recorded weeks.2026-10-23: No P/E valuation, close 178.88, recalculated for the week of 2026-10-242026-10-23: No P/E valuation, close 178.88, recorded live 2026-10-262026-10-30: No P/E valuation, close 237.60, recalculated for the week of 2026-10-312026-10-30: Significantly overvalued, close 237.60, recorded live 2026-11-02$180$200$220Oct 23Oct 25Oct 27Oct 28Oct 30
No P/E valuationNo P/E valuationSignificantly overvaluedLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

WeekCurrent P/EPremium to normal P/ERating
2026-10-24P/E 0.0not availableNo P/E valuation (recalculated)
2026-10-26P/E 0.0not availableNo P/E valuation
2026-10-31P/E 0.0not availableNo P/E valuation (recalculated)
2026-11-02P/E 601.5+156%Significantly overvalued ← now

Frequently asked questions

Is Glaukos stock overvalued?

At a current P/E of 601.5 versus its historical normal P/E of 234.5, Glaukos trades about 156% above its typical valuation, with a PEG of 4.46 on forward growth above 100%. tickerseer currently rates it significantly overvalued.

What is Glaukos's fair value and PEG?

Glaukos trades at a current P/E of 601.5 against a historical normal P/E of 234.5, a PEG of 4.46, and a forward growth estimate above 100%. Priced at its historical normal P/E of 234.5 on the same blended earnings, the 2026-10-30 close of $237.60 corresponds to about $92.60 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Glaukos changed?

tickerseer published no valuation rating on 2026-10-24, and rates it significantly overvalued as of 2026-11-02.

What is the analyst price target for Glaukos?

The mean Wall Street price target for Glaukos is $243.92 across 12 analysts, 2.7% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Medical devices. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track GKOS free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.